197 related articles for article (PubMed ID: 30788259)
1.
Parvizpour S; Razmara J; Pourseif MM; Omidi Y
Bioimpacts; 2019; 9(1):45-56. PubMed ID: 30788259
[No Abstract] [Full Text] [Related]
2. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
3. Implementation of Vaccinomics and In-Silico Approaches to Construct Multimeric Based Vaccine Against Ovarian Cancer.
Sufyan M; Shahid F; Irshad F; Javaid A; Qasim M; Ashfaq UA
Int J Pept Res Ther; 2021; 27(4):2845-2859. PubMed ID: 34690620
[TBL] [Abstract][Full Text] [Related]
4. Design and In Silico Validation of a Novel MZF-1-Based Multi-Epitope Vaccine to Combat Metastatic Triple Negative Breast Cancer.
Krishnamoorthy HR; Karuppasamy R
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992161
[TBL] [Abstract][Full Text] [Related]
5. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
6. Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitidis using comprehensive immunoinformatics approaches.
Rostamtabar M; Rahmani A; Baee M; Karkhah A; Prajapati VK; Ebrahimpour S; Nouri HR
Infect Genet Evol; 2019 Nov; 75():103992. PubMed ID: 31394292
[TBL] [Abstract][Full Text] [Related]
7. Designing, cloning and simulation studies of cancer/testis antigens based multi-epitope vaccine candidates against cutaneous melanoma: An immunoinformatics approach.
Khalid S; Guo J; Muhammad SA; Bai B
Biochem Biophys Rep; 2024 Mar; 37():101651. PubMed ID: 38371523
[TBL] [Abstract][Full Text] [Related]
8. Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches.
Saadi M; Karkhah A; Nouri HR
Infect Genet Evol; 2017 Jul; 51():227-234. PubMed ID: 28411163
[TBL] [Abstract][Full Text] [Related]
9. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
10. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
12. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S
Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381
[TBL] [Abstract][Full Text] [Related]
13. A candidate triple-negative breast cancer vaccine design by targeting clinically relevant cell surface markers: an integrated immuno and bio-informatics approach.
Kumar S; Shuaib M; Prajapati KS; Singh AK; Choudhary P; Singh S; Gupta S
3 Biotech; 2022 Mar; 12(3):72. PubMed ID: 35223358
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
15. Design of a Novel Recombinant Multi-Epitope Vaccine against Triple-Negative Breast Cancer.
Dariushnejad H; Ghorbanzadeh V; Akbari S; Hashemzadeh P
Iran Biomed J; 2022 Mar; 26(2):160-74. PubMed ID: 35090304
[TBL] [Abstract][Full Text] [Related]
16. Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis.
Carter JA; Matta B; Battaglia J; Somerville C; Harris BD; LaPan M; Atwal GS; Barnes BJ
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135347
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine.
Cen L; Zhang Z; Sun Y; Wu N; Shao J; Qian Z; Tian M; Ke Y; Liu B
Cancer Cell Int; 2024 Jul; 24(1):232. PubMed ID: 38961429
[TBL] [Abstract][Full Text] [Related]
18. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine.
Dorosti H; Eslami M; Negahdaripour M; Ghoshoon MB; Gholami A; Heidari R; Dehshahri A; Erfani N; Nezafat N; Ghasemi Y
J Biomol Struct Dyn; 2019 Aug; 37(13):3524-3535. PubMed ID: 30634893
[No Abstract] [Full Text] [Related]
19. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
20. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
